Types segmentation classifies the service portfolio by analytical methodology rather than end‑use. Molecular testing—including PCR, quantitative PCR, and next‑generation sequencing—captures the highest value share because of its central role in pathogen detection, oncology biomarker profiling, and pharmacogenomics. Immunoassay services, such as ELISA, chemiluminescent immunoassays, and lateral‑flow platforms, follow, driven by demand for protein‑based diagnostics and therapeutic monitoring. Hematology testing, encompassing complete blood counts, flow cytometry, and coagulation panels, serves routine clinical workflows and contributes a stable revenue stream. Microbiology services, which perform culture‑based, MALDI‑TOF, and susceptibility testing, are essential for infection‑control programs and antibiotic‑resistance surveillance. Finally, Pathology—including histopathology, cytopathology, and digital slide analysis—adds depth to the market by supporting tissue‑based diagnoses and companion‑diagnostic development. Each type adds distinct cost structures and margin profiles, collectively shaping the overall market size and informing provider specialization strategies within the broader market taxonomy.